Detecting circulating tumor cells: Current challenges and new trends

Theranostics

Volumn 3, Issue 6, 2013, Pages 377-394

  Hong, Bin ^a   Zu, Youli ^b  

^a TeloVISION LLC   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

CTC: circulating tumor cell; CTDNA: circulating tumor DNA; CTM: Circulating tumor microemboli; CTMat: circulating tumor materials; POCT: point of care test

Indexed keywords

DNA; TELOMERASE; TUMOR MARKER;

CANCER PROGNOSIS; CELL ASSAY; CELL FUNCTION; CIRCULATING TUMOR CELL; CLINICAL RESEARCH; COMBINATORIAL CHEMISTRY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENE AMPLIFICATION; HUMAN; MATHEMATICAL MODEL; MEDICAL RESEARCH; METASTASIS; MICROEMBOLISM; NONHUMAN; OVERALL SURVIVAL; POINT OF CARE TESTING; PROBABILITY SAMPLE; PROCESS DEVELOPMENT; PROGRESSION FREE SURVIVAL; REVIEW; SAMPLE SIZE; SURVIVAL PREDICTION; TARGET CELL; TREND STUDY;

CTC: CIRCULATING TUMOR CELL; CTDNA: CIRCULATING TUMOR DNA; CTM: CIRCULATING TUMOR MICROEMBOLI; CTMAT: CIRCULATING TUMOR MATERIALS; POCT: POINT-OF-CARE TEST.;

CYTOLOGICAL TECHNIQUES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84883152670     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5195     Document Type: Review

References (158)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
2. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011; 29(12): 1508-1511.
3. Fass L. Imaging and cancer: a review. Mol Oncol. 2008; 2(2): 115-52.
4. Rao GC, Larson C, Repollet M, Rutner H, Terstappen LW, O'hara SM, Gross S. Analysis of circulating tumor cells, fragments, and debris. United States Patent 7863012. 2011.
5. Asworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J. 1869; 14: 146-149.
6. Leary JF. Rare event detection and sorting of rare cells. In: Durack G, Robinson JP, ed. Emerging tools for cell analysis: advances in optical measurement technology, Wilmington, DE: Wiley-Liss; 2000: 49-72.
7. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev. 2011; 21(1): 50-58.
8. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA 1998; 95(8): 4589-4594.
9. Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry A. 2011; 79(2): 107-117.
10. Hong B, Mace M, Crowder R, Coleman T, He W, Szczepanski F, Feczko J, Lyzak J. Metastatic breast cancer detection and therapy monitoring using folate-targeting flow cytometry. J Clin Oncol. 2011; 29 (Suppl 27):23.
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20): 6897-6904.
12. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 9(1): 016003.
13. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH. A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004; 101(29): 10501-10504.
14. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, Nieva J. High speed detection of circulating tumor cells. Biosens Bioelectron. 2006; 21(10): 1893-1899.
15. Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L, Pazzagli M, Orlando C. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol. 2006; 37(6): 711-718.
16. Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat. 2006; 99(1): 63-69.
17. Rolle A, Günzel R, Pachmann U, Willen B, Höffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC ® is a predictor for relapse: A preliminary report. World J Surg Oncol. 2005; 3(1): 18.
18. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, Höffken K. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008; 26(8): 1208-1215.
19. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, Thorban S, Nekarda H, Siewert JR. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002; 49(4): 150-158.
20. Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003; 162: 149-155.
21. Bossolasco P, Ricci C, Farina G, Soligo D, Pedretti D, Scanni A, Deliliers GL. Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect Prev. 2002; 26(1): 60-63.
22. Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci. 2005; 42(2): 155-196.
23. Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007; 1162(2): 154-161.
24. Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Göttert J, McCarley RL, Nikitopoulos D, Murphy MC, Soper SA. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc. 2008; 130(27): 8633-8641.
25. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010; 107(43): 18392-18397.
26. Helzer KT, Barnes HE, Day L, Harvey J, Billings PR, Forsyth A. Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res. 2009; 69(19): 7860-7866.
27. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106(10): 3970-3975.
28. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumous cells in cancer patients by microchip technology. Nature 2007; 450(7173): 1235-1239.
29. Wang S, Liu K, Liu J, Yu ZT, Xu X, Zhao L, Lee T, Lee EK, Reiss J, Lee YK, Chung LW, Huang J, Rettig M, Seligson D, Duraiswamy KN, Shen CK, Tseng HR. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl. 2011; 50(13): 3084-3088.
30. Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis 2009; 30(18): 3289-3300.
31. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010; 16(20): 5011-5018.
32. Sun YF, Yang XR, Zhou J, Qiu SJ, Fan J, Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol. 2011; 137(8): 1151-73.
33. Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011; 9: 43.
34. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011; 192(3): 373-82.
35. Ghadially R. The role of stem and circulating cells in cancer metastasis. J Surg Oncol. 2011; 103(6): 555-7.
36. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007; 253(2): 180-204.
37. Hou JM, Krebs M, Ward T, Morris K, Sloane R, Blackhall F, Dive C. Circulating tumor cells, enumeration and beyond. Cancers 2010; 2(2): 1236-1250.
38. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010; 20(1): 96-99.
39. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19): 3213-3221.
40. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22): 6980-6986.
41. Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treat Rev. 2011; 37(8): 579-589.
42. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009; 35(5): 463-474.
43. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44(7): 946-953.
44. DeCaprio AP. Introduction to toxicologic biomarkers. In: DeCaprio AP, ed. Toxicologic Biomarkers, New York: Taylor and Francis Group; 2006: 6-8.
45. Saijo N. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Rev. 2011; 38(1): 63-7.
46. Nagaiah G, Abraham J. Circulating tumor cells in the management of breast cancer. Clin Breast Cancer 2010; 10(3): 209-216.
47. Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 2010; 50(4): 289-297.
48. Gion M. Serum tumour markers: from quality control to total quality management. Breast 2000; 9(6): 306-311.
49. Sturgeon C. Limitations of assay techniques for tumor markers. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, ed. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press. 2002: 65-82.
50. Gion M, Daidone MG. Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls. Eur J Cancer 2004; 40(17): 2613-2622.
51. Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ. 2002; 324: 477-480.
52. Parkinson DR, Dracopoli N, Gumbs Petty B, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JS, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10(1): 138.
53. Leary JF. Strategies for rare cell detection and isolation. In: Darzynkiewicz Z, Robinson JP, Crissman HA, ed. Methods in Cell Biology: Flow Cytometry, San Diego: Academic Press; 1994: 331-358.
54. Lalmahomed ZS, Kraan J, Gratama JW, Mostert B, Sleijfer S, Verhoef C. Circulating tumor cells and sample size: the more, the better. J Clin Oncol. 2010; 28(17): e288-e289.
55. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 2007; 71(3): 154-162.
56. Rosenblatt JI, Hokanson JA, McLaughlin SR, Leary JF. Theoretical basis for sampling statistics useful for detecting and isolating rare cells using flow cytometry and cell sorting. Cytometry 1997; 27(3): 233-238.
57. Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol. 2010; 2010: 426218.
58. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010; 102(10): 1495-502.
59. Cramb R. Guideline for point-of-care testing. In: Price CP, John A, Hicks J (ed) Point-of-Care Testing, Washington, DC: AACC Press; 2004: 155.
60. Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009; 76(6): 375-386.
61. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009; 14(11): 1070-1082.
62. Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K. What's new on circulating tumor cells? A meeting report. Breast Cancer Res. 2010; 12(4): 307.
63. Drenck N. Point of care testing in Critical Care Medicine: the clinician's view. Clin Chim Acta 2001; 307(1-2): 3-7.
64. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+CK+CD45- objects predict overall survival in castration- resistant prostate cancer. Ann Oncol. 2010; 21(9): 1851-1857.
65. Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW. External quality assurance of circulating tumor cell enumeration using the Cell- Search® system: A feasibility study. Cytometry B Clin Cytom. 2011; 80(2): 112-118.
66. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010; 16(21): 5233-43.
67. Fischer AH. Circulating tumor cells: seeing is believing. Arch Pathol Lab Med. 2009; 133(9): 1367-1369.
68. Titus K. Sizing up a role for circulating tumor cells. CAP today 2011; 25: 1-38.
69. Lim LS, Hu M, Huang MC, Cheong WC, Gan AT, Looi XL, Leong SM, Koay ES, Li MH. Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip. 2012; 12(21): 4388-96.
70. Ligthart ST, Coumans FA, Attard G, Cassidy AM, de Bono JS, Terstappen LW. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One. 2011; 6(11):e27419.
71. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33): 5287-5312.
72. Lilja H, Babaian R, Dowell B, Klee GG, Rittenhouse H, Semjonow A, Sibley P, Sokoll L, Stephan C. Tumor markers in prostate cancer. In: Sturgeon CM, Diamandis E, ed. Laboratory medicine practice guidelines: Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Washington, DC: The National Academy of Clinical Biochemistry, The American Association for Clinical Chemistry (AACC). 2009: 25.
73. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual, 7th ed. New York, USA: Springer. 2010.
74. Kilgore ML, Steindel SJ, Smith JA. Evaluating stat testing options in an academic health center: therapeutic turnaround time and staff satisfaction. Clin Chem. 1998; 44(8 Pt 1): 1597-603.
75. Louie RF, Tang Z, Shelby DG, Kost GJ. Point-of-Care Testing: Millennium Technology for Critical Care. Lab Medicine. 2000; 31: 402-408.
76. Bange A, Halsall HB, Heineman WR. Microfluidic immunosensor systems. Biosens Bioelectron. 2005; 20(12): 2488-2503.
77. Chen J, Li J, Sun Y. Microfluidic approaches for cancer cell detection, characterization, and separation. Lab Chip. 2012; 12(10): 1753-67.
78. Kaiser J. Medicine. Cancer's circulation problem. Science 2010; 327(5969): 1072-1074.
79. Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, Tai YC. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed. Microdevices. 2011; 13(1): 203-213.
80. Ameri K, Luong R, Zhang H, Powell AA, Montgomery KD, Espinosa I, Bouley DM, Harris AL, Jeffrey SS. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010; 102(3): 561-569.
81. Tan SJ, Lakshmi RL, Chen P, Lim WT, Yobas L, Lim CT. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron. 2010; 26(4): 1701-5.
82. Tan SJ, Yobas L, Lee GY, Ong CN, Lim CT. Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices. 2009; 11(4): 883-92.
83. Mohamed H, Murray M, Turner JN, Caggana M. Isolation of tumor cells using size and deformation. J Chromatogr A. 2009; 1216(47): 8289-95.
84. Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One. 2012; 7(4):e35976.
85. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 2010; 10(1): 27-9.
86. Bhagat AA, Hou HW, Li LD, Lim CT, Han J. Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation. Lab Chip. 2011; 11(11): 1870-8.
87. Sun J, Li M, Liu C, Zhang Y, Liu D, Liu W, Hu G, Jiang X. Double spiral microchannel for label-free tumor cell separation and enrichment. Lab Chip. 2012; 12(20): 3952-60.
88. Schiro PG, Zhao M, Kuo JS, Koehler KM, Sabath DE, Chiu DT. Sensitive and high-throughput isolation of rare cells from peripheral blood with ensemble-decision aliquot ranking. Angew Chem Int Ed Engl. 2012; 51(19): 4618-22.
89. Beveridge R. Circulating tumor cells in the management of metastatic breast cancer patients. Commun Oncol. 2007; 4(2): 79-82.
90. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009; 27(20): 3303-3311.
91. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3(5): 362-374.
92. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 66(17): 8319-8326.
93. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, van der Laak J, de Waal R, Mulders P, Oosterwijk E, Leenders W. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol. 2009; 219(3): 287-93.
94. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, Dive C. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 2011; 178(3): 989-996.
95. Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, Bréchot C, Paterlini-Bréchot P. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004; 39(3): 792-797.
96. Molnar B, Ladanyi A, Tanko L, Sréter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001; 7(12): 4080-4085.
97. Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J, Suman VJ, Harrington D, Torre-Bueno J, Bauer KD. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res. 2002; 8(5): 1085-91.
98. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, Assmann G, Zänker KS. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res. 1996; 56(20): 4556-4561.
99. Carr I. Experimental lymphatic metastasis. J Microsc. 1983; 131(Pt 2): 211-220.
100. Madhavan M, Srinivas P, Abraham E, Ahmed I, Mathew A, Vijayalekshmi NR, Balaram P. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol. 2001; 14(5): 423-427.
101. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976; 36(3): 889-94.
102. Zhang X, Nie D, Chakrabarty S. Growth factors in tumor microenvironment. Front Biosci. 2010; 15: 151-165.
103. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010; 288(1): 99-106.
104. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012; 30(5): 525-532.
105. Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008; 10(4): R69.
106. Hori H, Fujimori T, Fujii S, Ichikawa K, Ohkura Y, Tomita S, Ono Y, Imura J, Kuroda Y. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma. Dis Colon Rectum. 2005; 48(5): 938-45.
107. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002; 8(7): 2073-2084.
108. Fehm T, Solomayer EF, Meng S, Tucker T, Lane N, Wang J, Gebauer G. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005; 7(2): 171-185.
109. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975; 35(3): 512-516.
110. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10(24): 8152-8162.
111. Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology 2001; 58(3): 386-392.
112. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009; 15(3): 1032-1038.
113. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA Jr, Velculescu VE. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010; 2(20): 20ra14.
114. Kaiser J. Medicine. Keeping tabs on tumor DNA. Science 2010; 327(5969): 1074.
115. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007; 1775(1): 181-232.
116. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta 2010; 411(21-22): 1611-24.
117. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102(45): 16368-16373.
118. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev. 2002; 28(5): 255-71.
119. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11(6): 426-37.
120. Blackburn EH. Telomere states and cell fates. Nature 2000; 408(6808): 53-6.
121. Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B, Cathelineau X, Rozet F, Vallancien G, Sabatier L, Soria JC. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol. 2007; 18(3): 518-21.
122. Sapi E, Okpokwasili NI, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients. Cancer Detect Prev. 2002; 26(2): 158-67.
123. Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD, Sabatier L. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 1999; 5(5): 971-5.
124. Gauthier LR, Granotier C, Soria JC, Faivre S, Boige V, Raymond E, Boussin FD. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001; 84(5): 631-5.
125. Soria JC, Morat L, Durdux C, Housset M, Cortez A, Blaise R, Sabatier L. The molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol. 2002; 167(1): 352-6.
126. Maurelli R, Zambruno G, Guerra L, Abbruzzese C, Dimri G, Gellini M, Bondanza S, Dellambra E. Inactivation of p16INK4a (inhibitor of cyclin-dependent kinase 4A) immortalizes primary human keratinocytes by maintaining cells in the stem cell compartment. FASEB J. 2006; 20(9): 1516-8.
127. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010; 28(10): 517-525.
128. Xu Y, Yang X, Wang E. Review: Aptamers in microfluidic chips. Anal Chim Acta. 2010; 683(1): 12-20.
129. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249(4968): 505-10.
130. Vorhies JS, Nemunaitis JJ. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics 2007; 1(4): 367-376.
131. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002; 62(14): 4029-4033.
132. Phillips JA, Xu Y, Xia Z, Fan ZH, Tan W. Enrichment of cancer cells using aptamers immobilized on a microfluidic channel. Anal Chem. 2009; 81(3): 1033-1039.
133. Xu Y, Phillips JA, Yan J, Li Q, Fan ZH, Tan W. Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells. Anal Chem. 2009; 81(17): 7436-7442.
134. Cui CH, Zhao W, Guo D, Bose S, Philips J, Karnik R, Karp JM. Capture and detection of circulating tumour cells using three-dimensional, multivalent DNA aptamer network. Molecular Med TRI-CON 2011 (Poster Presentation), San Francisco, CA. 2011.
135. Zhao W, Ali MM, Brook MA, Li Y. Rolling circle amplification: applications in nanotechnology and biodetection with functional nucleic acids. Angew Chem Int Ed Engl. 2008; 47(34): 6330-7.
136. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH. Application of PET/CT in the development of novel anticancer drugs. Oncologist. 2008; 13(1): 25-38.
137. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012; 10(9): 1081-1087.
138. Hayes DF, Smerage J. Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer? Clin Cancer Res. 2008; 14: 3646.
139. Saad A, Abraham J. Role of tumor markers and circulating tumors cells in the management of breast cancer. Oncology. 2008; 22(7): 726-31.
140. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65(1-2): 109-121.
141. Alix-Panabières C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G, Vendrell JP. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods. 2005; 299(1-2): 177-188.
142. Alix-Panabières C, Vendrell JP, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007; 53(3): 537-539.
143. Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008; 14(16): 5013-5021.
144. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7): 1420-1430.
145. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol. 2008; 19(5): 891-897.
146. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8): 781-791.
147. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21): 6403-6409.
148. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1): 4218-4224.
149. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994; 86(11): 829-835.
150. Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med. 1996; 15(20): 2203-2213.
151. Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med. 2004; 23(7): 1159-1178.
152. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006; 25(1): 127-141.
153. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat. 2010; 122(1): 211-217.
154. CellSearch. Circulating Tumor Cell Epithelial Kit (IVD), CellSearch® Instructions for Use (IFU), No. e631500023. CellSearch. 2012.
155. Lustberg MB, Balasubramanian P, Miller B, Garcia Villa A, Carothers S, Michael B, Mrozek E, Ramaswamy B, Layman RM, Wesolowski R, Shapiro CL, Chalmers JJ. EpCAM-negative cancer-associated circulating cells in blood samples of women with triple-negative breast cancer. J Clin Oncol. 2011; 29 (Suppl): 11559.
156. Pecot CV, Bischoff FZ, Lin YG, Jaladurgam P, Merritt WM, Pircher TJ, Mikolajczyk S, Mayer JA, Wong K, Pham T, Bottsford-Miller JN, Stone RL, Celestino J, Nick AM, Eng C, Sood A. Clinical relevance of cytokeratin-negative circulating tumor cells. J Clin Oncol. 2011; 29 (Suppl): 21101.
157. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CKCTCs. Cancer Discov. 2011; 1(7): 580-6.
158. Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom. 2011; 80(2): 100-111.